+7-495-626-8046, +7-495-768-0434
понедельник-пятница, 10:00-18:00
Регистрация
|
+7-495-626-8046, +7-495-768-0434 понедельник-пятница, 10:00-18:00 |
Новости | Магазин | Журналы | Контакты | Правила | Доставка |
|
Вход Регистрация |
|||||
Ключевые слова:
Литература:
1. Oberg K. Pancreatic endocrine tumors. Semin. Oncol. 2010;
37: 594–618.
2. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine
tumors: Pancreatic endocrine tumors. Gastroenterology
2008; 135: 1469–1492.
3. Kulke M.H., Anthony L.B., Bushnell D.L. et al. NANETS
Treatment Guidelines: welldifferentiated neuroendocrine
tumors of the stomach and pancreas. Pancreas 2010; 39:
735–752.
4. Ekeblad S. Islet cell tumours. Adv. Exp. Med. Biol. 2010; 654:
771–789.
5. O’Toole D., Salazar R., Falconi M. et al. Rare functioning pan
creatic endocrine tumors. Neuroendocrinology 2006; 84:
189–195.
6. Falconi M., Plockinger U., Kwekkeboom D.J. et al. Welldif
ferentiated pancreatic nonfunctioning tumors/carcinoma.
Neuroendocrinology 2006; 84: 196–211.
7. Kaltsas G., Androulakis I.I., de Herder W.W. et al. Paraneo
plastic syndromes secondary to neuroendocrine tumours.
Endocr. Relat. Cancer. 2010; 17: R173–R193.
8. Jensen R.T., Niederle B., Mitry E. et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173–182.
9. Ellison E.C., Johnson J.A. The ZollingerEllison syndrome: a
comprehensive review of historical, scientific, and clinical
considerations. Curr. Probl. Surg. 2009; 46: 13–106.
10. Roy P., Venzon D.J., Shojamanesh H. et al. ZollingerEllison
syndrome: clinical presentation in 261 patients. Medicine
(Baltimore) 2000; 79: 379–411.
11. Jensen R.T., Berna M.J., Bingham M.D. et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular
pathogenesis, diagnosis, management and controversies.
Cancer 2008; 113(suppl): 1807–1843.
12. Gibril F., Schumann M., Pace A. et al. Multiple endocrine
neoplasia type 1 and ZollingerEllison syndrome. A prospective study of 107 cases and comparison with 1,009 patients
from the literature. Medicine (Baltimore). 2004; 83: 43–83.
13. Vanderveen K., Grant C. Insulinoma. Cancer Treat. Res.
2010; 153: 235–252.
14. Guettier J.M., Gorden P. Insulin secretion and insulinpro
ducing tumors. Expert Rev Endocrinol. Metab. 2010; 5:
217–227.
15. De Herder W.W., Niederle B., Scoazec J.Y. et al. Welldifferentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183–188.
16. Anlauf M., Garbrecht N., Henopp T. et al. Sporadic versus
hereditary gastrinomas of the duodenum and pancreas: distinct clinicopathological and epidemiological features. Wld
Med. J. 2006; 12: 5440–5446.
17. Kloppel G., Anlauf M. Gastrinoma – morphological aspects.
Wien Klin. Wochenschr. 2007; 119: 579–584.
18. Gibril F., Jensen R.T. Advances in evaluation and management of gastrinoma in patients with ZollingerEllison syndrome. Curr. Gastroenterol. Rep. 2005; 7: 114–121.
19. Anlauf M., Perren A., Meyer C.L. et al. Precursor lesions in
patients with multiple endocrine neoplasia type 1 associated
duodenal gastrinomas. Gastroenterology 2005; 128:
1187–1198.
20. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. World
Health Organization classification of tumors and genetics of
the digestive system, ed 1. Lyon, IARC, 2010.
21. Rindi G., Kloppel G., Alhman H. et al. TNM staging of foregut
(neuro)endocrine tumors: a consensus proposal including a
grading system. Virchows Arch. 2006; 449: 395–401.
22. Edge S.B., Byrd D.R., Compton C.C. et al. AJCC Cancer
Staging Manual, ed. 1. New York, Springer, 2010.
23. Fischer L., Kleeff J., Esposito I. et al. Clinical outcome and
longterm survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br. J. Surg. 2008; 95:
627–635.
24. Ekeblad S., Skogseid B., Dunder K. et al. Prognostic factors
and survival in 324 patients with pancreatic endocrine tumor
treated at a single institution. Clin. Cancer Res. 2008; 14:
7798–7803.
25. Pape U.F., Jann H. MullerNordhorn J. et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;
113: 256–265.
26. Zhao Y.P., Zhan H.X., Zhang T.P. et al. Surgical management
of patients with insulinomas: result of 292 cases in a single
institution. J. Surg. Oncol. 2011; 103: 169–174.
27. Casadei R., Ricci C., Rega D. et al. Pancreatic endocrine
tumors less than 4 cm in diameter: resect or enucleate? A singlecenter experience. Pancreas 2010; 39: 825–828.
28. Zerbi A., Falconi M., Rindi G. et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am. J.
Gastroenterol. 2010; 105: 1421–1429.
29. Niederle M.B., Hackl M., Kaserer K. et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence
and staging based on the WHO and European Neuro
endocrine Tumour Society classification: an analysis based
on prospectively collected parameters. Endocr. Relat. Cancer
2010; 17: 909–918.
30. Klimstra D.S., Modlin I.R., Coppola D. et al. The pathologic
classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:
707–712.
31. Weber H.C., Venzon D.J., Lin J.T. et al. Determinants of
metastatic rate and survival in patients with ZollingerEllison
syndrome: a prospective longterm study. Gastroenterology
1995; 108: 1637–1649.
32. Banasch M., Schmitz F. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien. Klin. Wschr.
2007; 119: 573–578.
33. Thom A.K., Norton J.A., Axiotis C.A. et al. Location, incidence
and malignant potential of duodenal gastrinomas. Surgery
1991; 110: 1086–1093.
34. Stabile B.E., Morrow D.J., Passaro E. Jr. The gastrinoma tri
angle: operative implications. Am. J. Surg. 1984; 147: 25–31.
35. PipeleersMarichal M., Kloppel G. Gastrinomas in MEN1.
N. Engl. J. Med. 1990; 323:349.
36. MacFarlane M.P., Fraker D.L., Alexander H.R. et al.
A prospective study of surgical resection of duodenal and
pancreatic gastrinomas in multiple endocrine neoplasia
type 1. Surgery 1995; 118: 973–980.
37. Garbrecht N., Anlauf M., Schmitt A. et al. Somatostatinpro
ducing neuroendocrine tumors of the duodenum and pan
creas: incidence, types, biological behavior, association with
inherited syndromes, and functional activity. Endocr. Relat.
Cancer 2008; 15: 229– 241.
38. Isidori A.M., Kaltsas G.A., Grossman A.B. Ectopic ACTH syndrome. Front Horm. Res. 2006; 35: 143–156.
39. Hoffmann K.M., Furukawa M., Jensen R.T. Duodenal neuroendocrine tumors: classification, functional syndromes,
diagnosis and medical treatment. Best. Pract. Res. Clin.
Gastroenterology 2005; 19: 675–697.
40. LevyBohbot N., Merle C., Goudet P. et al. Prevalence, char
acteristics and prognosis of MEN1associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE
(Groupe des Tumeurs Endocrines) registry. Gastroenterology
Clin. Biol. 2004; 28: 1075– 1081.
41. Yu F., Venzon D.J., Serrano J. et al. Prospective study of the
clinical course, prognostic factors and survival in patients with
longstanding ZollingerEllison syndrome. J. Clin. Oncol.
1999; 17: 615–630.
42. Jensen R.T. Natural history of digestive endocrine tumors; in
Mignon M, Colombel JF (eds): Recent Advances in Pathophysiology and Management of Inf lammatory Bowel Diseases
and Digestive Endocrine Tumors. Paris, Libbey Eurotext,
1999; 192–219.
43. Gibril F., Venzon D.J., Ojeaburu J.V. et al. Prospective study
of the natural history of gastrinoma in patients with MEN1:
definition of an aggressive and a nonaggressive form. J. Clin.
Endocrinol.Metab. 2001; 86: 5282–5293.
44. Jensen R.T. ZollingerEllison syndrome; in Doherty GM, Skogseid B (eds): Surgical Endocrinology: Clinical Syndromes.
Philadelphia, Lippincott Williams & Wilkins, 2001, 291–344.
45. Maton P.N., Gardner J.D., Jensen R.T. Cushing’s syndrome
in patients with ZollingerEllison syndrome. N. Engl. J. Med.
1986; 315: 1–5.
46. Cadiot G., Vuagnat A., Doukhan I. et al. Prognostic factors in
patients with ZollingerEllison syndrome and multiple
endocrine neoplasia type 1. Gastroenterology 1999; 116:
286–293.
47. Norton J.A., Jensen R.T. Resolved and unresolved controver
sies in the surgical management of patients with Zollinger
Ellison syndrome. Ann. Surg. 2004; 240: 757–773.
48. Goh B.K., Chow P.K., Tan Y.M. et al. Validation of five contemporary prognostication systems for primary pancreatic
endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J. Surg. 2011; 81:
79–85.
49. London J.F., Shawker T.H., Doppman J.L. et al. Zollinger–
Ellison syndrome: prospective assessment of abdominal US
in the localization of gastrinomas. Radiol. 1991; 178: 763–767.
50. Mathur A., Gorden P., Libutti S.K. Insulinoma. Surg. Clin. N.
Am. 2009;89:1105–1121.
51. Jonkers Y.M., Claessen S.M., Perren A. et al. DNA copy number status is a powerful predictor of poor survival in endocrine
pancreatic tumor patients. Endocr. Relat. Cancer. 2007; 14:
769–779.
52. Norton J.A., Fang T.D., Jensen R.T. Surgery for gastrinoma
and insulinoma in multiple endocrine neoplasia type 1. J. Nat.
Compr. Cancer 2006; 4: 148–153.
53. Goudet P., Murat A., CardotBauters C. et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a
comparative study on 21 cases among a series of 761 MEN1
from the GTE (Groupe des Tumeurs Endocrines). Wld J. Surg.
2009; 33: 1197– 1207.
54. Goudet P., Murat A., Binquet C. et al. Risk factors and caus
es of death in MEN1 disease. A GTE (Groupe d’Etude deTumeurs Endocrine cohort study among 758 patients. Wld
J. Surg. 2010; 34: 249–255.
55. Gibril F., Chen Y.J., Schrump D.S. et al. Prospective study
of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab.2003; 88:
1066–1081.
56. Krenning E.P., Bakker W.H., Kooij P.P. et al. Somatostatin
receptor scintigraphy with indium111DTPADPhe1
octreotide in man: metabolism, dosimetry and comparison
with iodine123Tyr3octreotide. J. Nucl. Med. 1992; 33:
652–658.
57. Osefo N., Ito T., Jensen R.T. Gastric acid hypersecretory states:
recent insights and advances. Curr. Gastroenterol. Rep.
2009; 11: 433–441.
58. Berna M.J., Hoffmann K.M., Serrano J. et al. Serum gastrin in
ZollingerEllison syndrome. I. Prospective study of fasting
serum gastrin in 309 patients from the National Institutes of
Health and comparison with 2,229 cases from the literature.
Medicine (Baltimore) 2006; 85: 295–330.
59. Corleto V.D., Annibale B., Gibril F. et al. Does the widespread
use of proton pump inhibitors mask, complicate and/or delay
the diagnosis of ZollingerEllison syndrome? Aliment.
Pharmacol. Ther. 2001; 15: 1555–1561.
60. Arnold R. Diagnosis and differential diagnosis of hypergastrinemia. Wien. Klin. Wschr. 2007; 119: 564–569.
61. Roy P., Venzon D.J., Feigenbaum K.M. et al. Gastric secretion in ZollingerEllison syndrome: correlation with clinical
expression, tumor extent and role in diagnosis – a prospective NIH study of 235 patients and review of the literature in
984 cases. Medicine (Baltimore) 2001; 80: 189–222.
62. Benya R.V., Metz D.C., Venzon D.J. et al. Zollinger–Ellison
syndrome can be the initial endocrine manifestation in
patients with multiple endocrine neoplasia type 1. Am. J.
Med. 1994; 97: 436–444.
63. Cadiot G., Houillier P., Allouch A. et al. Oral calcium toler
ance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients
with the ZollingerEllison syndrome. Groupe de Recherche
et d’Etude du Syndrome de ZollingerEllison. Gut. 1996; 39:
273–278.
64. Wynick D., Williams S.J., Bloom S.R. Symptomatic secondary
hormone syndromes in patients with established malignant
pancreatic endocrine tumors. N. Engl. J. Med. 1988; 319:
605–607.
65. Chiang H.C., O’Dorisio T.M., Huang S.C. et al. Multiple hor
mone elevations in patients with ZollingerEllison syndrome:
prospective study of clinical significance and of the develop
ment of a second symptomatic pancreatic endocrine tumor
syndrome. Gastroenterol. 1990; 99: 1565–1575.
66. Vinik A.I., Woltering E.A., Warner R.R. et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.
Pancreas 2010; 39: 713–734.
67. O’Toole D., Grossman A., Gross D. et al. ENETS consensus
guidelines for the standards of care in neuroendocrine
tumors: biochemical markers. Neuroendocrinology 2009; 90:
194–202.
68. Rehfeld J.F., Gingras M.H., Bardram L. et al. The Zollinger
Ellison syndrome and mismeasurement of gastrin.
Gastroenterol. 2011; 140: 1444–1453.
69. Weber H.C., Venzon D.J., Jensen R.T. et al. Studies on the
interrelation between ZollingerEllison syndrome,
Helicobacter pylori and proton pump inhibitor therapy.
Gastroenterol. 1997; 112: 84–91.
70. Jensen R.T. Consequences of longterm proton pump block
ade: highlighting insights from studies of patients with gastrinomas. Basic Clin. Pharmacol. Toxicol. 2006; 98: 4–19.
71. Oh D.S., Wang H.S., Ohning G.V. et al. Validation of a new
endoscopic technique to assess acid output in Zollinger–
Ellison syndrome. Clin. Gastroenterol. Hepatol. 2006; 4:
1467– 1473.
72. Berna M.J., Hoffmann K.M., Long S.H. et al. Serum gastrin in
ZollingerEllison syndrome. II. Prospective study of gastrin
provocative testing in 293 patients from the National
Institutes of Health and comparison with 537 cases from the
literature. Evaluation of diagnostic criteria, proposal of new
criteria, and correlations with clinical and tumoral features.
Medicine (Baltimore) 2006; 85: 331– 364.
73. Mignon M., Jais P., Cadiot G. et al. Clinical features and
advances in biological diagnostic criteria for ZollingerEllison
syndrome; in Mignon M, Jensen RT (eds): Endocrine Tumors
of the Pancreas: Recent Advances in Research and
Management. Series. Front Gastrointest Res. Basel, Karger,
1995; 23: 223–239.
74. Frucht H., Howard J.M., Slaff J.I. et al. Secretin and calcium
provocative tests in the ZollingerEllison syndrome: a
prospective study. Ann. Intern. Med. 1989; 111: 713–722.
75. Gibril F., Jensen R.T. ZollingerEllison syndrome revisited:
diagnosis, biologic markers, associated inherited disorders,
and acid hypersecretion. Curr. Gastroenterol. Rep. 2004; 6:
454–463.
76. Goldman J.A. Blanton W.P., Hay D.W. et al. Case report:
falsepositive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin.
Gastroenterol. Hepatol. 2009; 7: 600–602.
77. Niederle B. Hypergastrinemia – diagnosis and treatment.
Wien. Klin. Wschr. 2007; 119: 561–563.
78. De Herder W.W., O’Toole D., Rindi G. et al. ENETS consensus
guidelines for the management of patients with digestive
neuroendocrine tumors. Part 1. Stomach, duodeneum and
pancreas. Neuroendocrinology 2006; 84: 151–216.
79. Berna M.J., Annibale B., Marignani M. et al. A prospective
study of gastric carcinoids and enterochromaffinlike cells
changes in multiple endocrine neoplasia type 1 and Zollinger
Ellison syndrome: identification of risk factors. J. Clin.
Endocrinol. Metab. 2008; 93: 1582–1591.
80. Norton J.A., Cornelius M.J., Doppman J.L. et al. Effect of
parathyroidectomy in patients with hyperparathyroidism,
ZollingerEllison syndrome and multiple endocrine neoplasia
type I: a prospective study. Surgery 1987; 102: 958–966.
81. Waldmann J., Fendrich V., Habbe N. et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN1): a critical analysis of its value. Wld J. Surg. 2009; 33: 1208–1218.
82. Norton J.A., Venzon D.J., Berna M.J. et al. Prospective study
of surgery for primary hyperaparathyroidism in multiple
endocrine neoplasia type 1, and ZollingerEllison syndrome:
longterm outcome of a more virulent form of HPT. Ann. Surg.
2008; 247: 501–510.
83. Jensen R.T. Management of the ZollingerEllison syndrome
in patients with multiple endocrine neoplasia type 1. J. Intern.
Med. 1998; 243: 477–488.
84. Brandi M.L., Gagel R.F., Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 2001; 86: 5658–5671.
85. Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1).
Best. Pract. Res. Clin. Endocrinol. Metab. 2010; 24:
355–370.
86. Service F.J., Natt N., Thompson G.B. et al. Noninsulinoma
pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations
in Kir6.2 and SUR1 genes. J. Clin. Endocrinol. Metab. 1999;
84: 1582–1589.
87. Marsk R., Jonas E., Rasmussen F. et al. Nationwide cohort
study of postgastric bypass hypoglycaemia including 5,040
patients undergoing surgery for obesity in 1986–2006 in
Sweden. Diabetologia 2010; 53: 2307–2311.
88. Patti M.E., Goldfine A.B. Hypoglycaemia following gastric
bypass surgery – diabetes remission in the extreme?
Diabetologia 2010; 53: 2276–2279.
89. Van Bon A.C., Benhadi N., Endert E. et al. Evaluation of
endocrine tests. D: the prolonged fasting test for insulinoma.
Neth. J. Med. 2009; 67: 274–278.
90. Hirshberg B., Livi A., Bartlett D.L. et al. Fortyeighthour fast:
the diagnostic test for insulinoma. J. Clin. Endocrinol. Metab.
2000; 85: 3222–3226.
91. Vezzosi D., Bennet A., Fauvel J., et al. Insulin, Cpeptide and
proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur. J. Endocrinol.
2007; 157: 75–83.
92. Sundin A., Vullierme M.P., Kaltsas G. et al. ENETS guidelines
for the standards of care in patients with neuroendocrine
tumours: radiological examinations in patients with neuroendocrine tumours. Neuroendocrinology 2009; 90: 183.
93. Kwekkeboom D.J., Krenning E.P., Scheidhauer K. et al.
ENETS consensus guidelines for the standards of care in
neuroendocrine tumors: somatostatin receptor imaging with
111Inpentetreotide. Neuroendocrinology 2009; 90: 184–189.
94. Sundin A., Garske U., Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract. Res. Clin. Endocrinol.
Metab. 2007; 21: 69–85.
95. Rockall A.G., Reznek R.H. Imaging of neuroendocrine
tumours (CT/MR/US). Best Pract. Res. Clin. Endocrinol.
Metab. 2007; 21: 43–68.
96. Morrow E.H., Norton J.A. Surgical management of Zollinger
Ellison syndrome; state of the art. Surg. Clin. N. Am. 2009;
89: 1091–1103.
97. Fraker D.L., Norton J.A., Alexander H.R. et al. Surgery in
ZollingerEllison syndrome alters the natural history of gastrinoma. Ann. Surg. 1994; 220: 320–330.
98. Norton J.A., Fraker D.L., Alexander H.R. et al. Surgery
increases survival in patients with gastrinoma. Ann. Surg.
2006; 244: 410–419.
99. Norton J.A., Alexander H.R., Fraker D.L. et al. Does the use
of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with
ZollingerEllison syndrome? Ann. Surg. 2004; 239: 617–626.
100. Lebtahi R., Cadiot G., Sarda L. et al. Clinical impact of
somatostatin receptor scintigraphy in the management of
patients with neuroendocrine gastroenteropancreatic
tumors. J. Nucl. Med. 1997; 38: 853–858.
101. Doppman J.L., Miller D.L., Chang R. et al. Gastrinomas:
localization by means of selective intraarterial injection of
secretin. Radiology 1990; 174: 25–29.
102. Termanini B., Gibril F., Reynolds J.C. et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology
1997; 112: 335–347.
103. Alexander H.R., Fraker D.L., Norton J.A. et al. Prospective
study of somatostatin receptor scintigraphy and its effect on
operative outcome in patients with ZollingerEllison syndrome. Ann. Surg. 1998; 228: 228–238.
104. Anderson M.A. Carpenter S., Thompson N.W. et al. Endo
scopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am. J. Gastroenterol. 2000; 95: 2271–2277.
105. Ruszniewski P., Amouyal P., Amouyal G. et al. Localization
of gastrinomas by endoscopic ultrasonography in patients
with ZollingerEllison syndrom
Keywords:
